Vincristine sulfate as single-agent chemotherapy in a dog and a cat with malignant neoplasms

J Am Vet Med Assoc. 1990 Aug 15;197(4):504-6.

Abstract

A 12-year-old 4-kg spayed domestic shorthair cat with a poorly differentiated fibrosarcoma of the rostral aspect of the mandible and an 11-year-old 13-kg castrated dog of mixed breeding with pulmonary metastatic hemangiosarcoma were treated with 0.5 mg of vincristine sulfate/m2 of body surface, IV, weekly. Three months after beginning treatment, both animals had complete clinical remission. The role of this vinca alkaloid as a single agent for malignant neoplasms has seldom been discussed in the veterinary scientific literature. The results of these two cases indicate that single-agent vincristine sulfate chemotherapy is effective in the treatment of feline fibrosarcoma and canine hemangiosarcoma.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cat Diseases / drug therapy*
  • Cats
  • Dog Diseases / drug therapy*
  • Dogs
  • Female
  • Fibrosarcoma / drug therapy
  • Fibrosarcoma / veterinary*
  • Hemangiosarcoma / drug therapy
  • Hemangiosarcoma / secondary
  • Hemangiosarcoma / veterinary*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Lung Neoplasms / veterinary
  • Male
  • Mandibular Neoplasms / drug therapy
  • Mandibular Neoplasms / veterinary
  • Splenic Neoplasms / veterinary
  • Vincristine / therapeutic use*

Substances

  • Vincristine